Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Edwards Lifesciences but lowers the price target from $90 to $80.
September 09, 2024 | 6:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Matt Miksic maintains an Overweight rating on Edwards Lifesciences but lowers the price target from $90 to $80.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100